|
Renal safety of atazanavir-based regimens in human immunodeficiency virus (HIV) infected patients
|
|
|
Reported by Jules Levin
15th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV · October 15-17, 2010 · Brussels, Belgium
Sandrine Cure1, Florence Bianic2, Caroline Espinas2, Helene Hardy3, Lisa Rosenblatt3, Timothy Juday3 1OptumInsight, Uxbridge, UK; 2OptumInsight, Paris, France; and 3Bristol-Myers Squibb, Plainsboro, NJ, USA
![AASLD1.gif](../images/121213/121213-1/AASLD1.gif)
![AASLD2.gif](../images/121213/121213-1/AASLD2.gif)
![AASLD3.gif](../images/121213/121213-1/AASLD3.gif)
![AASLD4.gif](../images/121213/121213-1/AASLD4.gif)
![AASLD5.gif](../images/121213/121213-1/AASLD5.gif)
![AASLD6.gif](../images/121213/121213-1/AASLD6.gif)
![AASLD7.gif](../images/121213/121213-1/AASLD7.gif)
|
|
|
|
|
|
|